Addressing Tumor Heterogeneity & Multiple Cellular States: Is Combination Targeted Therapy the Answer?

Time: 4:00 pm
day: Conference Day 1


  • Unveiling research into the complexity of tumor heterogeneity in GBM
  • Reviewing preclinical data of one approach combining CT-179, an OLIG2 inhibitor, with EGFR inhibitors
  • Exploring areas of potential research to identify and test scientifically rational combinations of targeted therapeutics